FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
FibroBiologics, Inc. (FBLG)
Company Research
Source: GlobeNewswire
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are proceeding with plans to initiate in the second quarter of 2025 HOUSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced third quarter 2024 financial results and provided a corporate update. Third Quarter 2024 and Recent Highlights Joined the Russell 2000® Index effective at the open of US equity markets on Monday, July 1, 2024.Presented at a number of investor conferences including: the 2024 ThinkEquity Conference, BIO-Europe 2024, H.C. Wainwright 26th Annual Global Investment Summit, 2024 Maxim Virtual Summit, and the JonesTrading Healthcare Summit.Engaged Southern Sta
Show less
Read more
Impact Snapshot
Event Time:
FBLG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBLG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBLG alerts
High impacting FibroBiologics, Inc. news events
Weekly update
A roundup of the hottest topics
FBLG
News
- FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of SplenomegalyGlobeNewswire
- FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based TherapeuticsGlobeNewswire
- FibroBiologics, Inc. (NASDAQ: FBLG) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- FibroBiologics, Inc. (NASDAQ: FBLG) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
FBLG
Earnings
- 11/12/24 - Beat
FBLG
Sec Filings
- 11/12/24 - Form 10-Q
- 10/29/24 - Form 8-K
- 9/24/24 - Form 8-K
- FBLG's page on the SEC website